Neoprobe Corporation (OTC BB: NEOP) has focused their efforts on developing and commercializing novel biomedical products that address the critical intraoperative, diagnostic and therapeutic treatment needs of patients and physicians. The company’s main area of dedication is on improving cancer surgery outcomes by utilizing their market-leading gamma detection devices in conjunction with radiopharmaceutical agents.
- 17 years ago
QualityStocks
Neoprobe Corporation (OTC BB: NGNM)
Tags Rodman & Renshaw
Related Post
-
Soligenix Inc. (NASDAQ: SNGX) HyBryte(TM) Paves Way for Breakthrough Treatment for Rare Skin Cancer
The global rare disease treatment market was estimated at $195.2 billion in 2024 and is…
-
Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF) Is ‘One to Watch’
High-Grade Copper Opportunity: 100% ownership of the New Craigmont Project, one of British Columbia’s most promising…
-
QualityStocksNewsBreaks – Onar Holding Corporation (OTCQB: ONAR) Appoints Industry Veteran Jon Bond to Board of Directors
Onar (OTCQB: ONAR) announced the appointment of marketing pioneer Jon Bond to its board of…